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Abstract  
Food allergy(FA) is emerging as a global social issue. It is a potentially life threatening condition with a 
negative impact on quality of life of patients and their families. However, the current standard approach is 
relegated to the strict avoidance of triggering food(s) and the use of rescue medication in the case an 
allergic reaction occurs. 
Oral Immunotherapy (OIT) represent an  effective, active  treatment for FA, able  to increase the amount  
of food  that the patient  can intake without reaction during treatment (i.e desensitization) and reduces the 
risk  of potential of severe allergic reaction in the event of accidental ingestion. The key messages of the 
Guidelines of the European Academy of Allergy and Clinical Immunology (EAACI) suggest that OIT 
should be considered for children form around 4-5 years of age with symptoms suggestive of persistent 
IgE mediated food allergy. Caused by cow’s milk, hen’s egg or peanut. 
Currently, for OIT the use of fresh food or native food is advisable. OIT represents a typical hospital 
treatment administered by competent personnel i.e doctors and nurses. At present time there are just fresh 
food or native food available for OIT.  During many decades, the supportive management of food allergy 
consisted of avoidance of offending food and early recognition and treatment of anaphylaxis. Nowadays, 
looking into this matter, the time is ripe for practice of OIT in selected medical centers and under medical 
supervision with the goal of improving quality of life of patients and their families. 
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Introduction  
Food allergy(FA) is emerging as a global social issue. It is a potentially life threatening condition with a 
negative impact on quality of life of patients and their families. However, the current standard approach 
is relegated to the strict avoidance of triggering food(s) and the use of rescue medication in the case an 
allergic reaction occurs. Notwithstanding, an elimination diet may be difficult and frustrating, in 
particular for common foods (e.g. milk egg and peanut). 
Oral Immunotherapy (OIT) represent an effective, active treatment for FA, able to increase  the amount 
of food that the patient can intake without reaction during treatment (i.e desensitization) and reduces the 
risk  of potential of severe allergic reaction in the event  of accidental ingestion, In 2018 for the first time  
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the European guidelines have stated ,”OIT Can Be recommended as a treatment option to increase the 
threshold od reaction in children  with persistent cow’s milk, egg, or peanut allergy”. For such a 
promising curative treatment, well designed large studies are awaited in order to meet the current needs.  
Allergen Immunotherapy for food allergy (FA-AIT). 
AIT for food allergy refers to give to an allergic individual an increasing amount of an allergen (milk, 
egg, or peanut) in order to reduce symptoms due to the ingestion of previously offending allergic food. 
The three most frequent methods and routes are oral immunotherapy, sublingual (SLIT), and 
epicutaneous immunotherapy (EPIT). OIT consists of the immediate swallowing of the food allergen 
with the administration of increasing amount until it is tolerated at usual dose. OIT has the largest body 
of evidence among emerging therapy for persistent IgE mediated food allergy. SLIT patients take 
increased drops of no standardized extract that are placed under the tongue for few minutes and then 
swallow. SLIT doses are limited. Therefore, this method is safer but less effective than OIT: it may be 
related to the lack of standardization of available sublingual extract(s). In EPIT an allergen – containing 
patch is applied to the skin surface of the patients. Currently the results of preliminary studies regarding 
the safety are encouraging. EPIT offers a good safety profile. However, the prolonged (some days) 
application of patch containing food could be uncomfortable for patients. Overall, current data showing 
that efficacy of EPIT for the active treatment of persistentIgE mediated food allergy, still appears lower 
than what is achieved with OIT. 
The efficacy of oral Immunotherapy (OIT). 
Efficacy in clinical trials has typically defined by induction of desensitized state. Desensitization refers 
to the improvement in food challenge outcomes after therapy and relies on ongoing exposure to the 
allergen. The desensitization’s schedules for milk, egg or peanut had been shown to desensitize up to 
80% of patients with IgE mediated food allergy. However, the pivotal clinical issue is represented by 
the post – desensitization strategy. In fact the development of both immunological tolerance and clinical 
effectiveness, after successful desensitization with OIT, has not been defined to date. It is assumed that 
the post desensitization strategy could be different for each food. In other words, patients allergic to 
milk or egg in whom the natural history of the disease is “per se” favourable, are responders; hence OIT 
showing long- standing efficacy. On the other hand for patient allergic to peanut od tree nuts with 
natural history of food allergy less favorable: the therapies  in their current form are unlikely to produce 
long-standing immunologic changes. 
The need to bridge the gap between active treatment (OIT) and real life issues. 
The key messages of the Guidelines of the European Academy of Allergy and Clinical Immunology 
(EAACI) suggest that OIT should be considered for children form around 4-5 years of age with 
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symptoms suggestive of persistent IgE mediated food allergy. Caused by cow’s milk, hen’s egg or 
peanut. Currently, for OIT the use of fresh food or native food is advisable. The initial dosage of each 
increasing dose during build-up phase should be performed in clinical setting. Therefore, OIT represents 
a typical hospital treatment administered by competent personnel i.e. doctors and nurses. Because the 
length of the protocol, patients and their families must be extremely compliant , reliable and committed 
to treatment. In addition, for the fact that some important questions,  included the appearance  of adverse 
events  during OIT up-dosing regimen, require ongoing study, oral immunotherapy  needs to be  
performed , currently, in clinical setting. 
The need to bridge the gap between active treatment (OIT) and real life issues. 
The key messages of the Guidelines of the European Academy of Allergy and Clinical Immunology 
(EAACI) suggest that OIT should be considered for children form around 4-5 years of age with 
symptoms suggestive of persistent IgE mediated food allergy. Caused by cow’s milk, hen’s egg or 
peanut. Currently, for OIT the use of fresh food or native food is advisable. The initial dosage of each 
increasing dose during build-up phase should be performed in clinical setting. Therefore, OIT represents 
a typical hospital treatment administered by competent personnel i.e doctors and nurses. Because the 
length of the protocol, patients and their families must be extremely compliant , reliable and committed 
to treatment. In addition, for the fact that some important questions,  included the appearance  of adverse 
events during OIT up-dosing regimen, require ongoing study, oral immunotherapy  needs to be  
performed, currently, in clinical setting. 
Adverse Events 
In all immunotherapy trials safety is of the paramount importance. Mild reactions such as abdominal 
pain.Throat pruritus, gritty eyes, watery eyes, transient erythema and sneezing, usually do not require 
stopping desensitization. On the contrary, when rhinitis, dyspnea, asthma, generalized urticarial and 
hypotension occur alone or in combination OIT should be stopped and revaluated. Thus far, no fatality 
has been reported in the literature; some risk factori.e physical exercise, infections, menses are Known 
to increase the risk of reaction(s) especially during the maintenance phase of OIT. The appearance of 
eosinophilic esophagitis (EoE) is reported, however it is quite uncommon. In this context, before 
starting OIT the individual and familiar  clinical history should be negative  regarding persistent , severe  
esophagus and gastrointestinal diseases. 
Future Developments 
A biologics licenseapplication has been submitted to Food& Drug Administration (FDA) at the end of 
2018 for standardized OIT peanut products A similar application have been announced  in Europe for 
European Medicines Agency (EMA)  At present time there are just fresh food or native food available 
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for OIT.  Duringmany decades, the supportive management of food allergy consisted of avoidance of 
offending food and early recognition and treatment of anaphylaxis. Nowadays, looking into this matter, 
the time is ripe for practice of OIT in selected medical centers and under medical supervision with the 
goal of improving quality of life of patients and their families. Ultimately, the choice to giving hope and 
optimism to patient with persistent IgE mediated food allergy, represents in this field a decisive step 
forward.  
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